全州质量联盟缩短骨转移放疗疗程的进展
该研究分析全州质量联盟内4477例骨转移患者、6733个放疗计划,评估促进单次放疗(SFRT)和≤5次放疗的质量指标实施后的实践模式。质量指标实施后,无并发症转移的SFRT使用率从17.8%升至38.8%,任何转移的≤5次放疗使用率从44.2%升至63.9%,多种因素可预测短疗程使用。
要点
- 质量指标实施后无并发症骨转移SFRT使用率由17.8%升至38.8%。
- 任何骨转移≤5次放疗使用率由44.2%升至63.9%。
- 治疗年份较晚、距治疗机构较远、基线疲劳较高、非脊柱部位及医生执业年数较少预测短疗程。
核心结论
- 在全州质量联盟中缩短骨转移放疗疗程的努力已取得成功。
研究设计与样本
- 共纳入4477例患者、6733个放疗计划,其中1105例患者接受1465个无并发症转移计划,3247例患者接受4832个非立体定向体部放疗计划。
- 采用多变量逻辑回归(含和不含随机中心截距)校正中心聚类并评估与指标依从性的关联。
主要发现
- 无并发症转移的SFRT使用率从17.8%升至38.8%,任何转移的≤5次放疗使用率从44.2%升至63.9%。
- 两种模型中,治疗年份较晚、距治疗机构距离较长、基线疲劳较高、治疗部位非脊柱及医生执业年数较少预测更短疗程。
- 无并发症转移治疗部位>1个的患者接受SFRT的比值比较低。
- 正向计划、无并发症转移、再程治疗、姑息性意图、年龄≥80岁及ECOG体能状态≥2独立预测接受≤5次放疗。
临床怎么用
- 质量指标可有效促进骨转移短疗程放疗的采用,临床可参考预测因素优化患者选择。
- 对无并发症骨转移可优先考虑SFRT,对任何骨转移可优先考虑≤5次放疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: A large body of research has studied various fractionation regimens for radiation therapy (RT) targeting bone metastases, with evidence that courses of 5 or fewer fractions are isoeffective compared with longer courses. We analyzed practice patterns within a statewide quality consortium following the implementation of quality measures promoting single-fraction RT (SFRT) for uncomplicated metastases and ≤5 fractions for all metastases. METHODS AND MATERIALS: Consecutive patients receiving RT for bone metastasis from primary breast, lung, melanoma, prostate, or renal cancer(s) between March 1, 2018, and December 31, 2024, were prospectively enrolled in a statewide quality consortium. SFRT and ≤5-fraction quality metrics were implemented on January 1, 2020, and January 1, 2022, respectively. Patient, treatment, physician, and facility characteristics were collected, and multivariable logistic regression, with and without random center intercepts, was used to account for clustering by center and to assess associations with metric adherence. RESULTS: In total, 4477 patients were enrolled and received 6733 RT treatment plans, with 1105 patients receiving 1465 plans for uncomplicated metastases and 3247 patients receiving 4832 nonstereotactic body RT plans. The use of SFRT and ≤5-fraction RT for uncomplicated and any metastases increased from 17.8% to 38.8% and from 44.2% to 63.9%, respectively, after the implementation of quality measures. In both models, later years of treatment, longer distance to the treating facility, higher baseline fatigue, treatment site other than the spine, and fewer physician years in practice predicted shorter treatment courses. Patients with >1 site treated for uncomplicated metastases had lower odds of receiving SFRT. Forward planning, uncomplicated metastasis, retreatment, palliative intent, age ≥80 years, and an Eastern Cooperative Oncology Group performance status ≥2 independently predicted receipt of ≤5 fractions. CONCLUSIONS: Our efforts to shorten treatment courses for bone metastases have been successful. The number and variety of factors that predict the use of shorter courses reflect the complexity of clinical decision-making in the treatment of bone metastases.
引用
- Higgins LM, Yin HM, Griffith K, et al. Progress in Shortening Treatment Courses for Bone Metastases in a Statewide Quality Consortium. Adv Radiat Oncol. 2026. PMID: 41859301. doi:10.1016/j.adro.2026.102008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。